Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 95

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 95
---
 8,571,429 |
| Private shares                                                            |     |   |     400,000 |
| Representative shares                                                     |     |   |     200,000 |
| Total shares                                                              |     |   |  29,171,429 |
| Total funds in trust available for initial business combination           |     | $ | 195,000,000 |
| Public shareholders’ investment per ordinary share(1)                     |     | $ |       10.00 |
| Sponsor’s investment per ordinary share(2)                                |     | $ |        0.45 |
| Initial implied value per public share(3)                                 |     | $ |        9.75 |
| Implied value per share upon consummation of initial business combination |     | $ |        6.68 |

____________ (1)While the public shareholders’ investment is in both the public shares and the public rights, for purposes of this table the full investment amount is ascribed to the public shares only. (2)The total investment in the equity of the company by the sponsor is $4,035,000, consisting of (i) $35,000 paid by the sponsor for the founder shares, and (ii) $4,000,000 paid by the sponsor for 400,000 private units. For purposes of this table, the full investment amount is ascribed to the founder shares only. (3)Initial implied value per public share is defined as the funds available for the initial business combination (assuming the underwriters’ over -allotmentoption is not exercised and following payment of the underwriters’ deferred underwriting commissions) divided by the public shares issued of 20,000,000 (assuming the underwriters’ over -allotmentoption is not exercised). Based on these assumptions, each ordinary share would have an implied value of $6.68 per share upon completion of our initial business combination, representing an approximately 31.5% decrease from the initial implied value of $9.75 per public share. While the implied value of $6.68 per ordinary share upon completion of our initial business combination would represent a dilution to our public shareholders, this would represent a significant increase in value for our sponsor relative to the price it paid for each founder share. At $6.68 per ordinary share, the 8,571,429 ordinary shares that the sponsor would own upon completion of our initial business combination would have an aggregate implied value of approximately $57.26 million